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Abstract
Despite current control efforts, global tuberculosis (TB) incidence is decreasing slowly. New regimens that can shorten
treatment hold promise for improving treatment completion and success, but their impact on population-level transmission
remains unclear. Earlier models projected that a four-month regimen could reduce TB incidence by 10% but assumed that
an entire course of therapy must be completed to derive any benefit. We constructed a dynamic transmission model of TB
disease calibrated to global estimates of incidence, prevalence, mortality, and treatment success. To account for the efficacy
of partial treatment, we used data from clinical trials of early short-course regimens to estimate relapse rates among TB
patients who completed one-third, one-half, two-thirds, and all of their first-line treatment regimens. We projected
population-level incidence and mortality over 10 years, comparing standard six-month therapy to hypothetical shorter-
course regimens with equivalent treatment success but fewer defaults. The impact of hypothetical four-month regimens on
TB incidence after 10 years was smaller than estimated in previous modeling analyses (1.9% [95% uncertainty range 0.6–
3.1%] vs. 10%). Impact on TB mortality was larger (3.5% at 10 years) but still modest. Transmission impact was most sensitive
to the proportion of patients completing therapy: four-month therapy led to greater incidence reductions in settings where
25% of patients leave care (‘‘default’’) over six months. Our findings remained robust under one-way variation of model
parameters. These findings suggest that novel regimens that shorten treatment duration may have only a modest effect on
TB transmission except in settings of very low treatment completion.
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Introduction
Tuberculosis (TB) is the second leading cause of death from a
single infectious agent: it is estimated that one-third of the world
population is infected with TB, with 8.7 million developing active
disease and 1.4 million dying each year [1]. In the last 25 years,
over 20 new drugs to treat human immunodeficiency virus (HIV)
infection have been developed; by contrast, the primary first-line
treatment for TB–requiring six months of therapy with moderately
toxic agents–has remained unchanged [2–5]. Globally, approxi-
mately 7% of TB patients who receive first-line therapy do not
complete this six-month course [1], but in some settings this
percentage is as high as 30–50% [6]. Incomplete treatment results
in higher risk of relapse, continued disease transmission, and
emergence of drug resistance [6]. If the goal of global elimination
of TB by 2050 is to be attained, it is widely recognized that new
drugs capable of curing TB more rapidly will be necessary [1,7].
For the first time in decades, novel treatment regimens hold the
realistic promise of shortening the standard six-month first-line TB
treatment course [8–10]. If their efficacy is confirmed in ongoing
trials, these novel regimens could reduce healthcare costs [11] and
improve both patient satisfaction and treatment outcomes [12,13].
However, a key consideration for public health programs is the
potential of novel TB regimens to impact population-level
epidemiological outcomes, specifically future incidence and
mortality. The expectation that shorter treatment will help control
transmission has been a key driver of ongoing efforts by global
organizations to develop new drugs and regimens for TB [14,15].
Mathematical (transmission) models are important tools for
estimating the potential impact of new technologies and informing
policy [16]. Prior models have projected long-term TB incidence
reductions of 10–40% from the introduction of shorter-course TB
regimens [17,18]. However, these models have generally assumed
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that TB therapy is ineffective unless a full course is completed. In
reality, patients who receive no treatment can experience
spontaneous resolution [19], and follow-up from early randomized
trials demonstrates that partial courses of treatment (two to four
months) can achieve durable cure in a considerable proportion of
patients [20–22]. Using data from these trials, we constructed a
mathematical model of TB treatment (Figure 1) to more
realistically assess the impact of novel, shorter-course first-line
treatment regimens (four months, two months, and two weeks) on
population-level transmission and compare our results to previous
estimates.
Methods
Model Structure
We used ordinary differential equations to construct a
deterministic compartmental model of TB transmission
(Figure 1). This model resembles previous TB models [23,24] in
its basic design but adds additional structure to reflect the process
of TB treatment.
Specifically, we model TB treatment as consisting of four
sequential phases: weeks 1–2, weeks 3–8, months 3–4, and months
5–6. Individuals with active TB must be successfully diagnosed
before they can initiate the first phase of treatment. Upon starting
treatment, the bacillary burden decreases rapidly, and individuals
on treatment are assumed to be non-infectious after the first two
weeks [25,26]. In each treatment phase, individuals may either
die, leave care (‘‘default’’), or progress to the next phase (Table 1).
Patients who default either return to the active (infectious) state or
advance to the ‘‘cured/recovered’’ state; the probability of cure
increases with increasing duration of therapy, as informed by data
from clinical trials of two-month and four-month treatment
regimens [20–22]. We took the conservative stance that all
individuals who relapse within the longest follow-up period from
any available trial (60 months) receive no benefit from treatment
and thus return immediately to the active TB compartment; all
other individuals are assumed to be cured. Thus, for example, the
proportion cured among individuals taking more than four, but
less than six, months of standard therapy was set equal to the
proportion of individuals who completed a four-month regimen of
streptomycin, isoniazid, rifampin, and pyrazinamide and had no
long-term relapse. These individuals–like all others who are
latently infected or cured (therapeutically or spontaneously)–
remain susceptible to reinfection.
Treatment scenarios
Our primary outcomes were TB incidence and mortality at 10
years, comparing continued use of the current six-month regimen
to the introduction of novel, shorter regimens (four months, two
months and two weeks), assuming that these shorter regimens will
have the same efficacy as the current regimen. We defined
treatment efficacy as the proportion of people completing the full
course of TB therapy who are cured without long-term relapse.
Since efficacy is assumed to be similar for all regimens, shorter
regimens are modeled as superior to standard therapy in three
ways. First, the proportion of treatment completion is higher; for
Figure 1. Model compartments and transition rates. Boxes represent the proportions of the modeled population that are susceptible to
infection, latently infected with M. tuberculosis, in active TB disease, under treatment, or cured. Arrows represent the transitions between various
states, including up to four sequential phases of treatment. Rates of transition are described in the Methods section and Appendix S1.
doi:10.1371/journal.pone.0096389.g001
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example, any individual who defaults during months 5–6 of a six-
month regimen would have completed therapy on a four-month
regimen. Second, completion of any treatment phase represents
completion of a greater proportion of total treatment in shorter-
course regimens, and we model the probability of cure as a
function of the proportion of total treatment course completed
(beyond the first two weeks). Thus, for example, taking two months
of treatment equates to 33% completion of the six-month regimen
but 50% completion of a four-month regimen. Probabilities of
cure at each phase of treatment are shown in Figure 2. Third, in
addition to improving cure rates among those completing therapy,
we assume that shorter regimens avert TB-related mortality that
otherwise occurs during stages of treatment after the shorter
regimen is completed – though this effect may not be large enough
to result in statistically superior outcomes in a clinical trial.
Model assumptions, calibration and data inputs
The model was designed to be simple and transparent, in order
to increase the interpretability of results and comparability with
previous models of shortened treatment duration. We modeled a
hypothetical, non-age-structured population with a life expectancy
of 70 years, assuming no net migration or population growth. We
excluded non-pulmonary TB, as such cases are unlikely to be
infectious and constitute only 14% of notified cases worldwide [1].
Although poor treatment adherence may lead to primary drug
resistance, our focus was on first-line regimens, so we did not
separately model the transmission of drug-resistant TB. There is
no evidence that novel treatment regimens would have differential
indications or impact according to HIV status; we therefore
modeled our population to reflect the weighted average of WHO-
reported outcomes (including both HIV-associated and non-HIV-
associated TB). As our focus was on treatment rather than
diagnosis, we assumed the ‘‘active TB’’ compartment to be a
weighted average of smear-positive and smear-negative pulmonary
TB, thus avoiding the requirement to explicitly parameterize
smear status. These simplifying procedures allowed us to generate
a model with a minimum of parameters and assumptions, ensuring
that model behavior was driven by the parameters of greatest
interest and limiting the potential for results to be driven by
extraneous factors.
We first set the rate at which individuals with active TB are
diagnosed and initiate treatment (‘‘TB treatment rate’’) such that
the duration of active TB matched the WHO-estimated duration
of disease (prevalence/incidence), using the most recent data
available at the time of the analysis (2012); at steady-state, this rate
corresponded to 67% of active TB cases initiating treatment
before death or spontaneous resolution, similar to WHO global
estimates [1]. Using a modified downhill simplex approach, we
then estimated a transmission parameter (number of secondary
infections per infectious person-year) that resulted in the 2012
WHO-estimated global TB incidence at steady-state to within
60.1. We used the steady-state model as our initial population,
both for mathematical rigor and to improve the ability for others
to replicate and generalize our results.
Other model parameters were taken as fixed, based on best
available literature; parameters relating to TB mortality and
treatment failure, default and success were based on WHO data
(Table 2) [1]. Additional details on input derivation are provided
in Appendix S1 in Table S2. Primary model outcomes are
obtained using the reference values in Tables 1 and 2 as inputs.
Sensitivity and uncertainty analyses
We performed wide sensitivity analyses on model data
parameters to assess the robustness of our findings and their
generalizability to alternative epidemiological settings. We selected
upper and lower bounds for each parameter based on literature
estimates (Tables 1, 2). For parameters that strongly influenced TB
incidence (transmission rate, proportion of infections resulting in
‘‘primary progressive’’ TB, protection from reinfection in the
latent TB state), we evaluated scenarios corresponding to 50–
200% change from the baseline incidence. We therefore evaluated
settings of ‘‘moderate’’ (62 per 100,000/year), ‘‘global reference’’
(125 per 100,000/year), ‘‘very high’’ (250 per 100,000/year), and
‘‘extreme’’ (1,000 per 100,000/year) incidence [1], by varying the
Table 1. Model inputs for TB treatment outcomes, by treatment phase.
Outcome Treatment phase Reference(s)
Week 0–2 Week 3–8 Month 3–4 Month 5–6 Total
Duration 2 weeks 6 weeks 2 months 2 months 2 weeks-6 months
Percentage defaulting (sensitivity
analysis range)
0.2% (0–1.0%) 1.9% (0–4.1%) 2.7% (0–5.7%) 2.2% (0–4.8%) 7.0% (2–15%) [1,6]
Percentage dying (sensitivity analysis
range)
1.1% (0.5–2.1%) 1.3% (0.6–2.5%) 0.8% (0.4–1.7%) 0.8% (0.4–1.7%) 4.0% [1,28–30]
Percentage completing treatment period 98.7% 96.8% 96.5% 96.9% -
Cumulative percentage remaining in
therapy
98.7% 95.0% 92.1% 89.0% 89.0%
doi:10.1371/journal.pone.0096389.t001
Figure 2. Proportion cured after default, by treatment phase
and regimen duration. The proportion cured after default in a six-
month treatment regimen was based on outcomes of early TB
treatment clinical trials. For each hypothetical shortened treatment
regimen, the proportion cured after default is increased according to
the proportion of the total treatment duration completed. Detailed
examples of calculations are provided in Appendix S1.
doi:10.1371/journal.pone.0096389.g002
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transmission rate, primary progression and latent protection
parameters individually. The modeled impact of shorter regimens
on incidence remained similar regardless of which of these three
parameters was varied. For simplicity, therefore, we present only
results from varying the proportion of primary progression.
Similarly, we evaluated the proportion of treatment default, which
varies widely across settings, by constructing alternative scenarios
of ‘‘low’’ (3%), ‘‘global reference’’ (7%), ‘‘high’’ (12.5%), and ‘‘very
high’’ (25%) default. We assessed all possible combinations of
incidence/default scenarios in a two-way sensitivity analysis.
In order to further assess the range of results that might be
expected across a wide range of epidemic settings (in which
parameter values would be expected to vary simultaneously), we
performed a probabilistic uncertainty analysis using Latin Hyper-
cube Sampling to generate at least 1,000 probabilistic combina-
tions of values for all model parameters simultaneously [27].
Values for each parameter were sampled from beta distributions
with the baseline value as the mode, upper and lower bounds of
650% baseline, and shape parameter (alpha) of 4. We excluded
simulations resulting in unrealistic scenarios for a globally
representative epidemic (i.e., greater than 650% variation in
baseline incidence [62–188 per 100,000]) and verified that this did
not result in a biased selection of individual parameters (Figure S3
in Appendix S1). Uncertainty ranges for model outcomes were
calculated using the 2.5th and 97.5th percentiles of 1,000
simulations after restricting results in this fashion.
We also assessed the ability of our model to replicate the results
of previous models of shorter TB treatment that did not consider
the efficacy of partial treatment. We modified our model’s
transition parameters such that default always resulted in
treatment failure (and return to the infectious active TB state),
and we set the probability of treatment success upon completion of
shorter regimens using data inputs from one such model (six-
month regimen: 84%; four-month regimen: 89%; two-month
regimen: 96%) [17]. Finally, we assessed the effect of changes in
structural assumptions (details in Appendix S1). All simulations
were performed using R, version 3.0.1 (R Foundation for
Statistical Computing).
Results
Epidemiologic impact of shorter treatment regimens
Primary model outcomes are shown in Figure 3. Starting from a
steady-state ‘‘global reference’’ rate of 125 new cases per 100,000
population, introducing a four-month treatment regimen reduced
incidence by only 1.9% [95% uncertainty range 0.6–3.1%] over
10 years; the shorter two-month and two-week regimens reduced
incidence by 4.3% [1.8–7.0%] and 6.7% [3.0–10.2%], respec-
tively. For all treatment durations, the rate of incidence reduction
peaked in years 2–3, suggesting that the greatest impact of shorter
TB regimens on transmission would occur within the first few
years of implementation. The impact on TB mortality was greater
but still modest. The four-month, two-month, and two-week
regimens reduced mortality by 3.5%, 7.5%, and 13.1% at 10
years, respectively (Figure 3).
Scenario analyses
We assessed the robustness of our findings to a variety of
epidemic settings, reflecting the wide variations in disease
transmission and treatment infrastructure across countries. Short-
ening the average duration of infectiousness before diagnosis from
16 to 2 months while maintaining the baseline incidence
attenuated the impact of the four-month regimen (1.0% incidence
reduction at 10 years). The impact of novel regimens on TB
incidence was greater (2.4% 10-year reduction) in a very high-
incidence scenario (250 per 100,000/year, similar to Ethiopia [1])
and attenuated (1.0% 10-year reduction) in a moderate-incidence
scenario (62 per 100,000/year, similar to China [1]), reflecting the
relative proportion of incident TB due to recent transmission in
such settings. Effects on TB mortality were similar in both
scenarios (3.2% [moderate incidence] – 3.7% [very high
incidence] 10-year reduction). Finally, in the setting of low
treatment default (3%), the four-month regimen decreased
incidence by only 0.7% at 10 years, whereas in settings of high
(12.5%) and very high (25%) default, incidence fell by 3.4% and
7.1%, respectively. To compare our findings with those of previous
models, we constructed a scenario in which partial treatment was
Table 2. Selected key input parameters for estimating transmission impact of shorter TB regimens*.
Parameter Reference value Sensitivity analysis range Reference(s)
Baseline annual incidence (per 100,000 population) 125 62–250 [1]
Transmissions per person-year{ 8.5 6.8–20 [31]
% infections progressing immediately to active TB{ 15% 5.0–21.0% [23]
Protection from reinfection w/prior infection 60% 30–100% [32–34]
Relative infectiousness during treatment phase 1 (first 2 weeks)
compared to active TB
50% 0–100% Assumed
Annual risk of reactivation from latent to active TB 0.05% 0.03–0.10% [35,36]
Annual risk of relapse after completed treatment 0.10% 0.05–0.20% [37]
Probability of failure among those who complete treatment 2% 1–4% [1]
Life expectancy, years 70 40–100 [38]
Active TB mortality, per year 20% 10–40% [19]
Self-cure without treatment, per year 20% 10–40% [19]
Case detection ratio 67% 62–70% [1]
* Additional model parameters are listed in Table 1
{The transmission rate was initially calibrated to TB incidence. In sensitivity analyses, incidence was varied by varying one of these two parameters (both gave similar
results); the two parameters were then also varied over the ranges listed, with the other parameter varied to maintain constant incidence.
doi:10.1371/journal.pone.0096389.t002
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assumed to have no efficacy, with additional parameter changes as
described in the Methods. This resulted in incidence reductions of
10.3% at 10 years and 10.5% at 35 years with a four-month
regimen.
Sensitivity analyses
In one-way sensitivity analyses, no scenario resulted in an
incidence decrease of more than 2.7% at 10 years with four-month
therapy (Figure 4a). Other than the protection afforded by latent
infection, the two most influential parameters were the baseline
TB incidence and the treatment default proportion. We therefore
conducted a two-way sensitivity analysis on these parameters; the
most extreme combination (incidence 1,000 per 100,000; 25%
default) led to 8.3% incidence reduction at 10 years with four-
month therapy (Figure 4b). In a moderate-incidence setting (100
per 100,000/year) with a well-functioning TB control program
(3% default at six months), the four-month regimen was projected
to reduce incidence by 0.6% [95% uncertainty range 0.1–1.1%] at
10 years, whereas in a very high-incidence scenario (300 per
100,000/year) with poor follow-up (20% default) incidence
decreased by 7.2% [3.0–11.6%]. Even in the high-burden
scenario, the uncertainty analysis yielded incidence reductions of
$10% in only 8.5% of simulations.
Discussion
This mathematical model of TB treatment and transmission
suggests that novel treatment regimens are unlikely to have the
dramatic impact on global TB incidence projected by earlier
models; specifically, we found that immediate implementation of a
four-month treatment regimen could reduce TB incidence by
1.9% and mortality by 3.5% over 10 years compared to a six-
month regimen of equal efficacy, suggesting that previous analyses
significantly overestimated the impact of shortened treatment
duration. The impact of novel shorter-course TB regimens is likely
to be greater in high-incidence, high-default settings, but in most
settings these regimens should be recommended on the basis of
their clinical effectiveness and potential cost-effectiveness rather
than a large projected impact on population-level incidence and
transmission.
As with all modeling analyses, we made assumptions about
structure (e.g., uninfected, latent, active TB compartments),
parameter values, and transmission dynamics (e.g., homogeneous
mixing). However, we selected a model that would minimize
extraneous assumptions, in order to clearly demonstrate relation-
ships between input parameters and outputs. We also varied data
parameters and structural assumptions to explore a wide range of
natural history, treatment, and epidemiological scenarios, with no
significant change in our findings. Our results suggest more
modest benefits compared to prior analyses that modeled the
impact of shorter regimens by increasing the total proportion of
patients completing treatment while implicitly assuming no
effectiveness of partial treatment (even up to 5.9 months of a six-
month treatment course completed). When we likewise assumed
that partial treatment had zero efficacy, we were able to replicate
the findings of an earlier model [17] with our simpler, more
transparent framework (10.5% [current model] vs. 10% [prior
model] incidence reduction at 35 years with a four-month
regimen). This suggests that the difference in projected epidemi-
ological impact between previous analyses and the present model
is attributable not to differences in the structure or parameter
values of the two models, but rather to our incorporation of partial
treatment efficacy [17].
In our model, even a two-week regimen resulted in an incidence
reduction of only 6.7% at 10 years. However, if TB treatment
could be made so short and non-toxic (similar to many typical
antibiotic regimens) that clinicians were willing to prescribe it
empirically, without waiting for diagnostic confirmation, such
regimens might reduce transmission by removing delays and
barriers to treatment after diagnosis; these ancillary benefits of
shorter-course therapy are not incorporated in our model and may
lead to underestimation of the true impact of new regimens. This
underestimation is likely to be greater for ultra-short-course
regimens (e.g., two weeks) than for regimens (e.g., four months)
Figure 3. Reduction in TB incidence and mortality achievable from shorter-course regimens over time. Assuming TB incidence of 125
per 100,000/year, and 7% overall treatment default, the implementation of a four-month regimen vs. a six-month regimen results in a 1.9% reduction
in incidence at 10 years (vertical line marks year 10 after introduction of a new regimen). Hypothetical two-month and two-week regimens decrease
incidence by 4.3% and 6.7% respectively.
doi:10.1371/journal.pone.0096389.g003
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that may not be perceived as qualitatively shorter than current
treatment. Because our estimates of partial treatment efficacy
relied on clinical trials of regimens that are similar to the currently
recommended first-line regimen, they may not reflect the efficacy
of future regimens that will likely include new classes of drugs. Still,
our findings remained robust to wide variations around the partial
efficacy parameters in sensitivity analyses. It is important to note
that novel treatment regimens are expected to provide benefits in
terms of patient satisfaction, cost-effectiveness, and increased
barrier to drug resistance, and should thus remain a high research
priority. However, the primary justification for deploying these
regimens should be that they are beneficial to patients and health
systems, not the expectation of significant impact on transmission.
Limitations of this analysis include the simplicity of the model;
the model was based on global TB epidemic data and therefore
may not generalize to unique epidemiological settings (e.g., prisons
and other areas of high drug resistance) or settings of lower TB
incidence. We intentionally chose a simple approach in order to
generate a transparent modeling framework that could demon-
strate the transmission impact of novel regimens in a population
that is generalizable, through sensitivity analysis, to a number of
potential epidemiologic settings. Nevertheless, our results are not
precisely calibrated to any single population, and our sensitivity
analyses suggest that the effect of shorter treatment duration on
population-level incidence may vary considerably depending on
the epidemic setting, with the most important drivers of impact
being TB incidence and treatment default proportion. Although
our results remained robust in a wide range of sensitivity analyses,
our estimation of global average reductions in incidence may not
reflect the likely greater impact of shorter regimens in settings of
very high incidence and very high treatment default, nor do they
take into account co-dynamics with HIV. It will therefore be
Figure 4. Sensitivity analyses. One-way and two-way sensitivity analyses of the difference in incidence at year 10 after introduction of a four-
month regimen versus continuation of a six-month regimen of equal efficacy. A) One-way sensitivity analyses. Input parameters were varied one at a
time within ranges consistent with estimates in the literature (Table 2). In this figure, we varied incidence by varying the transmission rate, but no
major differences were observed when we instead varied the proportion of rapid progression to active disease. The parameters that most
significantly influenced the impact of a four-month vs. six-month treatment regimen were the degree of protection afforded by latent infection,
incidence of TB disease, and the proportion of treated patients who default at baseline. B) Two-way sensitivity analysis. The two most influential
parameters likely to vary widely across epidemiological settings (TB disease incidence and proportion of treated patients defaulting at baseline) were
varied simultaneously in a stepwise manner, within a range consistent with estimates in the literature and various epidemiologic settings (Table 2).
Colors correspond to the range of projected incidence reduction for each combination of baseline incidence and treatment default and selected
countries with representative estimates are shown. The highest estimates for both treatment default (25%) and baseline incidence (1,000 per
100,000/year) resulted in no more than 8.3% incidence reduction with a four-month vs. six-month regimen at 10 years.
doi:10.1371/journal.pone.0096389.g004
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important to conduct further analyses with models that are closely
calibrated to unique epidemic and health system resource settings,
particularly those (e.g., Southern Africa) with the highest rates of
both TB incidence and HIV/TB co-infection.
In summary, we have used a simple, generalizable modeling
framework, populated by data from randomized trials, to
demonstrate that novel shorter-course TB treatment regimens
are unlikely to reduce incidence by more than 3% (upper bound of
uncertainty range for a four-month regimen) to 7% (two-month
regimen) over 10 years in most epidemiological settings. The
projection of greater impact by previous models appears to reflect
the assumption that TB therapy confers no benefit until the entire
course is complete. Future studies should assess the benefits of
novel regimens in specific settings with high TB incidence,
treatment default, and TB-HIV co-infection, as these settings are
where novel first-line regimens may have the most impact. While
awaiting the results of such studies, novel TB regimens should be
prioritized based on their ability to improve individual clinical
outcomes and provide potential benefits to an overburdened
healthcare system, not the expectation that they will dramatically
reduce TB incidence and mortality at the population level.
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